Atlanta Cancer Care - Clinical Trial Preview Page
	
    








	
	




	




	










	




	
	Home




	




	
	About Us




	




	
	Services




	




	
	Clinical Trials




	




	
	Insurance




	




	
	FAQs




	




	
	Links




	




	
	Locations




	




	
	Privacy Practices




	




	
	Employment Opportunities




	




	
	ACC Foundation Information




	




			
	
	
	





    




    
    
    





    




	





Clinical trials provide an opportunity to participate in the latest research being done to identify new cancer treatments.  Atlanta Cancer Care participates in clinical trials which use chemotherapy drugs, and/or other drugs which affect cancer cells.  Participation is voluntary, and eligibility is determined by specific criteria.  The medical team will carefully consider each patient's potential for enrollment in a clinical trial.  Patients are encouraged to let their physician know if they are interested in participating in a clinical trial.




Under the direction of a Registered Pharmacist (RPh), an Advanced Oncology Certified Nurse (AOCN), and Clinical Research Coordinators, several clinical trials are under way at 
four of Atlanta Cancer Care's locations.  In addition, each of our locations may participate in other clinical trials administered through hospitals, pharmaceutical companies and other research entities.




Atlanta Cancer Care uses a state-of-the-art system to identify and monitor patients participating in clinical trials. The following is a brief listing of the clinical trials being conducted by Atlanta Cancer Care at the Tower (Perimeter), Roswell, 
Cumming, Stockbridge, and Decatur locations.



Advanced Cancer
  
    Diagnosis    Treatment    Eligibility Criteria  
  
    Metastatic Lung, Colon, and Breast (upon approval)    Avastin observational study    Patients who have been on Avastin < or = 3 months for lung, colon, or breast
  
Breast Cancer
  
    Diagnosis    Treatment    Eligibility Criteria  
  
    Metastatic Breast Cancer    Bevacizumab in Combination with Chemotherapy    1)  Previously untreated metastatic breast cancer
2)  Histologically or cytologically confirmed adenocarcinoma of the breast
3)  ECOG 0-1		  
  
    ErbB2 Overexpressing Breast Cancer    Paclitaxel, Trastuzumab +/- Lapatinib    1) Confirmed invasive breast cancer with stage IV disease
2) Tumor tissue must be available
3) Measurable disease		  
Colorectal Cancer
  
    Diagnosis    Treatment    Eligibility Criteria  
  
    Metastatic Colorectal Cancer    Bevacizumab, Oxaliplatin, 5-FU/ Leucovorin or Cetuximab, Bevacizumab, 5-FU/Leucovorin    1) Metastatic colorectal cancer patients who have had no prior treatment
2) Histologically or cytologically confirmed colorectal cancer with metastatic disease documented on diagnostic imaging studies
3) ECOG 0-1		  
  
    Metastatic Colorectal Cancer    FOLFIRI and Panitumumab    1) Metastatic adenocarcinoma of the colon or rectum that cannot be cured by surgical resection
2) Failure of first line therapy with FOLFOX/Avastin
3) Measurable disease		  
Erythropoiesis Stimulating Therapy
  
    Diagnosis    Treatment    Eligibility Criteria  
Esophageal Cancer
  
    Diagnosis    Treatment    Eligibility Criteria  
  
    Esophageal Cancer Stage I-III    Oxaliplatin, Docetaxel, and Capecitabine with Concurrent Radiation    1)  No previous treatment for esophageal cancer
2)  Histologically documented adenocarcinoma or squamous cell carcinoma of the esophagus or GE junction
3)  Must be a surgical candidate
4)  ECOG 0-1		  
Gastrointestinal Stromal Tumors (GIST)
  
    Diagnosis    Treatment    Eligibility Criteria  
  
    Gastrointestinal Stromal Tumors    Observational study of patients with GIST    All patients diagnosed with GIST  
Lung Cancer
  
    Diagnosis    Treatment    Eligibility Criteria  
  
    Non Small Cell Lung Cancer (Adjuvant)    Tarceva/Placebo    1) Confirmed diagnosis of stage IB-IIIA non small cell lung cancer
2) Complete surgical resection
3) Completion of 4 cycles of standard, 2-drug, platinum based chemotherapy
4) Tumor tissue must be availabe		  
Lymphoma
  
    Diagnosis    Treatment    Eligibility Criteria  
Monoclonal Gammopathy of Unknown Significance (MGUS)
  
    Diagnosis    Treatment    Eligibility Criteria  
Multiple Myeloma
  
    Diagnosis    Treatment    Eligibility Criteria  
  
    Multiple Myeloma    Velcade, Ascorbic Acid, and Melphalan    1)  Previously untreated  
     multiple myeloma
2)  Must meet all laboratory 
     criteria
3)  Karnofsky performance
     status > 60		  
Prostate Cancer
  
    Diagnosis    Treatment    Eligibility Criteria  
  
    Hormone Refractory Prostate Cancer    Taxotere and GM-CSF    1)  Histologically confirmed metastatic adenocarcinoma of the prostate with progressive disease, despite androgen deprivation
2)  Karnofsky > 60
3)  No prior systemic chemotherapy, immunotherapy, or radiotherapy to > 25% of bone marrow		  


* Disclaimer: The information provided above briefly summarizes eligibility criteria for each study.  Additional evaluations and tests are required to determine if a patient meets all eligibility criteria to participate in a clinical trial.



For more information about clinical trials at Atlanta Cancer Care, please contact our Clinical Research Department at 404-851-2359 (Tower location) or 678-287-1241 (Roswell location).






	To learn more about clinical trials in general, please try these resources:




	




	clinicaltrials.com
	
	centerwatch.com
	
	cancer.gov
	
	cancernet.com
	
	





			




    





			
    
    




    






			








	
	




	
	Privacy Policy  |  Site Map
	Copyright © 2003-2007, Atlanta Cancer Care. All Rights Reserved.